Cor­morant nears the close of fifth pri­vate health­care fund as biotech in­dus­try sees green­er pas­tures

Cor­morant As­set Man­age­ment has been on a tear late­ly.

The Boston-based firm plans to close its fifth pri­vate health­care fund this month, founder Bi­hua Chen said. The firm has reached its $400 mil­lion tar­get for the fund, Chen told End­points News on Fri­day.

The in­vest­ment firm, a lit­tle over a decade old, has tak­en part in mul­ti­ple megarounds for biotechs in re­cent weeks for a va­ri­ety of ar­eas (epilep­sy cell ther­a­py, on­col­o­gy small mol­e­cules, plus a mus­cle-pre­serv­ing weight loss com­bi­na­tion treat­ment) and suc­cess­ful­ly brought its sec­ond spe­cial pur­pose ac­qui­si­tion com­pa­ny on­to the Nas­daq when many oth­er in­vestors backed away.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER